CA62857B1094
© PR Newswire
20.01.2026
MYND
LISTED
CSE
Promethean ActivSuite Expands Compatibility with ChromeOS Integration
News Preview
ChromeOS integration delivers seamless, cross-platform access to Promethean's interactive teaching tools for educators worldwideSEATTLE, Jan. 20, 2026 /PRNewswire/ -- Promethean, a global education and workplace technology company and a brand of Mynd.ai (NYSE American: MYND), today announced a major expansion of its flagship Promethean ActivSuite®...
Themefolio
Profiler
Peergroup
© PR Newswire
10.11.2025
MYND
LISTED
CSE
Mynd.ai's Promethean brand Forges Strategic Relationship with Augment Me to Advance AI-Powered Learning
News Preview
SEATTLE, Nov. 10, 2025 /PRNewswire/ -- Mynd.ai, Inc ("Mynd" or the Company) (NYSE American: MYND) today announced that its subsidiary, Promethean, a leading global tech company, is proud to announce a strategic relationship with Augment Me Inc., a trailblazer in artificial intelligence solutions designed to enhan...
Themefolio
Profiler
Peergroup
© Newsfile
01.05.2025
MYND
LISTED
CSE
CSE Bulletin: Suspension - MYND Life Sciences Inc. (MYND)
News Preview
Toronto, Ontario--(Newsfile Corp. - Le 1 mai/May 2025) - Effective immediately, MYND Life Sciences Inc. is suspended pursuant to CSE Policy 3. The suspension is considered a Regulatory Halt as defined in National Instrument 23-101 Trading Rules. A cease trade order has been issued by the British Columbia Securities Commissions....
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© PR Newswire
01.05.2025
MYND
LISTED
CSE
Canadian Investment Regulatory Organization Trading Halt - MYND
News Preview
VANCOUVER, BC, May 1, 2025 /CNW/ - The following issues have been halted by CIRO:
Company: MYND Life Sciences Inc.
CSE Symbol: MYND
All Issues: Yes
Reason: Cease Trade Order
Halt Time (ET): 8:00 AM
CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
23.01.2026
© Newsfile
09.04.2025
MYND
LISTED
CSE
Management Cease Trade Order Status Report
News Preview
Vancouver, British Columbia--(Newsfile Corp. - April 9, 2025) - Mynd Life Sciences Inc. (CNSX: MYND) ("Mynd" or the "Company") announced on March 3, 2025 the Company was granted a management cease trade order (MCTO) under the National Policy 12-203 of the Canadian Securities Administrators ("NP 12-203") imposed against certain insiders of the Compa...
Themefolio
Profiler
Peergroup
© Newsfile
25.03.2025
MYND
LISTED
CSE
Management Cease Trade Order Status Report
News Preview
Vancouver, British Columbia--(Newsfile Corp. - March 24, 2025) - MYND Life Sciences Inc. (CSE: MYND) ("MYND" or the "Company") announced on March 3, 2025, the Company was granted a management cease trade order (MCTO) under the National Policy 12-203 of the Canadian Securities Administrators ("NP 12-203") imposed against certain insiders of the Comp...
Themefolio
Profiler
Peergroup
© Newsfile
04.03.2025
MYND
LISTED
CSE
Management Cease Trade Order Granted
News Preview
Vancouver, British Columbia--(Newsfile Corp. - March 3, 2025) - Mynd Life Sciences Inc. (CNSX: MYND) ("Mynd" or the "Company") announces that it has been advised by its external auditors (the "Auditors") that they will not be in a position to complete their work on the Company's annual consolidated financial statements for the year ended October 31...
Themefolio
Profiler
Peergroup
© Newsfile
12.02.2025
MYND
LISTED
CSE
MYND Life Sciences Announces Shares for Debt Transaction
News Preview
Vancouver, British Columbia--(Newsfile Corp. - February 11, 2025) - MYND Life Sciences Inc. (CSE: MYND) (OTC Pink: MYNDF) ("MYND" or the "Company") a clinical-stage life sciences company committed to the development and commercialization of drug therapies and diagnostics to improve the monitoring and treatment of depression, today announced that it...
Themefolio
Profiler
Peergroup
© Newsfile
18.01.2025
MYND
LISTED
CSE
MYND Life Sciences Announces the Issuance of 4,000,001 Shares at $0.71/share
News Preview
Vancouver, British Columbia--(Newsfile Corp. - January 17, 2025) - MYND Life Sciences (CSE: MYND) (OTC Pink: MYNDF) ("MYND" or the "Company") a clinical-stage life sciences company committed to the development and commercialization of drug therapies and diagnostics to improve the monitoring and treatment of depression, today announced that the Boar...
Themefolio
Profiler
Peergroup
© Newsfile
10.01.2025
MYND
LISTED
CSE
MYND Life Sciences Announces Successful Conclusion of Debenture Settlement Agreement and Leadership Transition
News Preview
Vancouver, British Columbia--(Newsfile Corp. - January 10, 2025) - MYND Life Sciences (CSE: MYND) (OTC Pink: MYNDF) ("MYND" or the "Company") a clinical-stage life sciences company committed to the development and commercialization of a biomarker tool for monitoring depression, today announced that the application to end its debenture has been succ...
Themefolio
Profiler
Peergroup
© Newsfile
22.11.2024
MYND
LISTED
CSE
MYND Life Sciences Announces Strategic Debt Reduction and New Board Member Appointment
News Preview
Vancouver, British Columbia--(Newsfile Corp. - November 22, 2024) - MYND Life Sciences (CSE: MYND) (OTCQB: MYNDF) ("MYND" or the "Company"), a leader in mental health diagnostics and treatments, today announced two significant strategic decisions aimed at strengthening the company's financial position and governance. These moves demonstrate a stro...
Themefolio
Profiler
Peergroup
© Newsfile
13.11.2024
MYND
LISTED
CSE
MYND Life Sciences Announces Proposed Share Issuance to Remove Debenture and $3.440 M in debt on business
News Preview
Vancouver, British Columbia--(Newsfile Corp. - November 12, 2024) - MYND Life Sciences (CSE: MYND) (OTCQB: MYNDF) ("MYND" or the "Company") a clinical-stage life sciences company committed to the development and commercialization of a biomarker tool for monitoring depression, today announced that subject to regulatory approval, it is proposing to i...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Newsfile
30.01.2024
MYND
LISTED
CSE
MYND Life Sciences Announces New Director & Update on the Proposed Merger with Cava Healthcare Inc.
News Preview
Vancouver, British Columbia--(Newsfile Corp. - January 30, 2024) - MYND Life Sciences (CSE: MYND) (OTCQB: MYNDF) ("MYND" or the "Company") The Company is pleased to welcome Ms. Laurie Bakke who was recently appointed to MYND's Board. Ms. Bakke joins as an independent non-executive director, bringing over 30 years of experience in the banking and f...
Themefolio
Profiler
Peergroup
© Newsfile
06.12.2023
MYND
LISTED
CSE
MYND Life Sciences Inc. Announces the Appointment of Mr. John Campbell as President and Chief Executive Officer
News Preview
Vancouver, British Columbia--(Newsfile Corp. - December 5, 2023) - MYND Life Sciences (CSE: MYND) (OTCQB: MYNDF) ("MYND" or the "Company"), a pioneering biopharmaceutical research and development company committed to advancing treatments for patients coping with chronic and acute neurological and inflammatory diseases, is delighted t...
Themefolio
Profiler
Peergroup
© Newsfile
04.12.2023
MYND
LISTED
CSE
Dr. Lyle Oberg Appointment as Board Chair of Alberta Health Services and Executive Chair of MYND Life Sciences
News Preview
Vancouver, British Columbia--(Newsfile Corp. - December 4, 2023) - MYND Life Sciences (CSE: MYND) (OTCQB: MYNDF) ("MYND" or the "Company"), We are delighted to announce the appointment of Mynd Life Sciences current CEO and Director, the Hon. Dr. Lyle Oberg, E.C.A., as the Board Chair of Alberta Health Services (AHS). Dr. Oberg brings...
Themefolio
Profiler
Peergroup
© Newsfile
26.10.2023
MYND
LISTED
CSE
MYND Life Sciences Inc. Announces Non-Binding LOI to enable merger with Cava Healthcare Inc.
News Preview
Potential merger to create new industry leader.Vancouver, British Columbia--(Newsfile Corp. - October 25, 2023) - MYND Life Sciences (CSE: MYND) (OTCQB: MYNDF) ("MYND" or the "Company"), a pioneering biopharmaceutical research and development company dedicated to revolutionizing treatments for patients battling relentless neurological and inflammat...
Themefolio
Profiler
Peergroup
© Newsfile
11.09.2023
MYND
LISTED
CSE
MYND Life Sciences Announces Update on Payment Obligations Under Unsecured Convertible Debentures
News Preview
MYND Life Sciences was formed to commercialize proprietary biomarker diagnostic tests and novel therapeutics for patients suffering from MDD, TRD and other neuro-inflammatory disordersVancouver, British Columbia--(Newsfile Corp. - September 11, 2023) - MYND Life Sciences Inc. (CSE: MYND) (OTCQB: MYNDF) ("MYND" or the "Company") today announces it h...
Themefolio
Profiler
Peergroup
© Newsfile
09.05.2023
MYND
LISTED
CSE
MYND Life Sciences Inc. Has Management CTO Revoked
News Preview
Vancouver, British Columbia--(Newsfile Corp. - May 9, 2023) - MYND Life Sciences (CSE: MYND) (OTCQB: MYNDF) ("MYND" or the "Company"), a biopharmaceutical research and development company creating innovative precision medicines for patients with relentless neurological diseases, today announced details regarding its Management Cease...
Themefolio
Profiler
Peergroup
© Newsfile
26.04.2023
MYND
LISTED
CSE
MYND Life Sciences Inc. Provides Default Status Report
News Preview
Vancouver, British Columbia--(Newsfile Corp. - April 25, 2023) - MYND Life Sciences (CSE: MYND) (OTCQB: MYNDF) ("MYND" or the "Company"), a biopharmaceutical research and development company creating innovative precision medicines for patients with relentless neurological diseases, today announced details regarding its Management Cease Trade Order....
Themefolio
Profiler
Peergroup
© Newsfile
12.04.2023
MYND
LISTED
CSE
MYND Life Sciences Inc. Provides Default Status Report
News Preview
Vancouver, British Columbia--(Newsfile Corp. - April 12, 2023) - MYND Life Sciences (CSE: MYND) (OTCQB: MYNDF) ("MYND" or the "Company"), a biopharmaceutical research and development company creating innovative precision medicines for patients with relentless neurological diseases, today announced details regarding its Management Cea...
Themefolio
Profiler
Peergroup
© Newsfile
29.03.2023
MYND
LISTED
CSE
MYND Life Sciences Inc. Announces Non-Binding MOU with German Based Oxygen Handel and Provides Default Status Report
News Preview
Global expansion as MYND executes non-binding MOU with German based Oxygen Handel.Vancouver, British Columbia--(Newsfile Corp. - March 28, 2023) - MYND Life Sciences (CSE: MYND) (OTCQB: MYNDF) ("MYND" or the "Company"), a biopharmaceutical research and development company creating innovative precision medicines for patients with relentless neurolog...
Themefolio
Profiler
Peergroup
© Newsfile
14.03.2023
MYND
LISTED
CSE
MYND Life Sciences Inc. Achieves a Major Milestone and Provides Default Status Report
News Preview
Identification of a potent, monomolecular non-hallucinogenic analog of psilocybin 100 times stronger than psilocybin.Vancouver, British Columbia--(Newsfile Corp. - March 14, 2023) - MYND Life Sciences Inc. (CSE: MYND) (OTCQB: MYNDF) ("MYND" or the "Company"), a biopharmaceutical research and development company creating innovative precision medicin...
Themefolio
Profiler
Peergroup
© Newsfile
02.03.2023
MYND
LISTED
CSE
MYND Life Sciences Inc. Granted Management Cease Trade Order
News Preview
Vancouver, British Columbia--(Newsfile Corp. - March 1, 2023) - MYND Life Sciences Inc. (CSE: MYND) ("MYND" or the "Company") announces that it has been advised by its external auditors (the "Auditors") that they will not be in a position to complete their work on the Company's annual consolidated financial statements for the year ended October 31,...
Themefolio
Profiler
Peergroup
© Newsfile
09.02.2023
MYND
LISTED
CSE
MYND Life Sciences Announces the Sale of Leasehold Tenant Improvements and Health Canada Cannabis License
News Preview
Vancouver, British Columbia--(Newsfile Corp. - February 9, 2023) - MYND Life Sciences Inc. (CSE: MYND) (OTCQB: MYNDF) ("MYND" or the "Company"), a biopharmaceutical research and development company creating innovated and precision medicines for patients with relentless neurological diseases, is pleased to announce the disposition of the Company's...
Themefolio
Profiler
Peergroup
© Newsfile
10.08.2022
MYND
LISTED
CSE
MYND Life Sciences Announces Stock Option Grant
News Preview
Vancouver, British Columbia--(Newsfile Corp. - August 10, 2022) - Mynd Life Sciences Inc. (CSE: MYND) (OTCQB: MYNDF) ("Mynd" or the "Company"), a biopharmaceutical research and development company creating innovative precision medicines and diagnostic solutions for patients with relentless neurological diseases, announces a stock option grant purs...
Themefolio
Profiler
Peergroup
© Newsfile
30.06.2022
MYND
LISTED
CSE
Mynd Life Sciences Terminates Proposed Transaction with Tidal Psychedelics
News Preview
Vancouver, British Columbia--(Newsfile Corp. - June 29, 2022) - Mynd Life Sciences Inc. (CSE: MYND) (OTCQB: MYNDF) ("Mynd" or the "Company") announces that it has terminated the non-binding memorandum of understanding ("MOU") to acquire all the issued and outstanding shares of Tidal Care Inc. o/a Tidal Psychedelics ("Tidal") as disclosed in Mynds'...
Themefolio
Profiler
Peergroup
© Newsfile
17.06.2022
MYND
LISTED
CSE
MYND Life Sciences Announces Chief Scientific Officer, Dr. Wilf Jefferies, Induction as a National Academy of Inventors Fellow
News Preview
Vancouver, British Columbia--(Newsfile Corp. - June 17, 2022) - Mynd Life Sciences Inc. (CSE: MYND) (OTCQB: MYNDF) ("Mynd" or the "Company"), a biopharmaceutical research and development company creating innovative precision medicines and diagnostic solutions for patients with relentless neurological diseases, is pleased to announce that...
Themefolio
Profiler
Peergroup
© Newsfile
01.06.2022
MYND
LISTED
CSE
MYND Life Sciences Announces New Testing Methodologies for Measuring Cellular Responses to Microdosing with Psilocybins
News Preview
Vancouver, British Columbia--(Newsfile Corp. - June 1, 2022) - Mynd Life Sciences Inc. (CSE: MYND) (OTCQB: MYNDF) ("Mynd" or the "Company"), a biopharmaceutical research and development company creating innovative precision medicines and diagnostic solutions for patients with relentless neurological diseases, today announced positive prec...
Themefolio
Profiler
Peergroup
© Newsfile
21.04.2022
MYND
LISTED
CSE
MYND Life Sciences Announces $3.5 Million Share Offering
News Preview
Vancouver, British Columbia--(Newsfile Corp. - April 21, 2022) - MYND Life Sciences Inc. (CSE: MYND) (OTCQB: MYNDF) ("MYND" or the "Company"), is pleased to announce that it plans to undertake a non-brokered private placement offering (the "Offering") of common shares in share capital of the Company ("Shares") to raise gross proceeds of a...
Themefolio
Profiler
Peergroup
© Newsfile
16.03.2022
MYND
LISTED
CSE
MYND Life Sciences Executes a Non-Binding MOU with Tidal Psychedelics
News Preview
MYND expresses the intention to acquire all the issued and outstanding shares of Tidal PsychedelicsVancouver, British Columbia--(Newsfile Corp. - March 16, 2022) - MYND Life Sciences Inc. (CSE: MYND) (OTCQB: MYNDF) ("MYND" or the "Company"), a biopharmaceutical research and development company creating innovative precision medicines for patients w...
Themefolio
Profiler
Peergroup
© Newsfile
09.03.2022
MYND
LISTED
CSE
MYND Life Sciences Inc. Announces the Recruitment of a Senior Operations and Research Manager
News Preview
Vancouver, British Columbia--(Newsfile Corp. - March 9, 2022) - MYND Life Sciences Inc. (CSE: MYND) (OTCQB: MYNDF) ("MYND" or "the Company") announces the hiring of a Senior Operations and Research Manager and the resignation of a company officer.MYND is pleased to announce the hiring of Dr. Chaahat S.B Singh as the Company's Senior Opera...
Themefolio
Profiler
Peergroup
© Newsfile
16.06.2021
MYND
LISTED
CSE
CSE Bulletin: Appointment of Market Maker
News Preview
Toronto, Ontario--(Newsfile Corp. - June 16, 2021) Effective Thursday, Jun 17, 2021, W.D. Latimer Co. Limited will be responsible for the Guaranteed Fill volume and automatic execution of odd lots for the symbols below. Market Maker: W.D. Latimer Co. Limited Dealer number: 036 Symbol: ACT, GAIA,MXT and MYND...
Themefolio
Profiler
Peergroup
© Newsfile
25.05.2021
MYND
LISTED
CSE
CSE Bulletin: New Listing - MYND Life Sciences Inc. (MYND)
News Preview
Toronto, Ontario--(Newsfile Corp. - Le 25 mai/May 2021) - The common shares of MYND Life Sciences Inc., have been approved for listing on the CSE. Listing and disclosure documents will be available at www.thecse.com on the trading date. Mynd is a life sciences based neuro-pharmaceutical drug development company advancing...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
